A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

Study Identifier
M10-459
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Hepatitis
  • Study Drug
  • ABT-333
  • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18 - 65 Years

    Protocol Summary

    The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 17665
    Anaheim, California, United States, 92801
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 17367
    Los Angeles, California, United States, 90036
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 17672
    Los Angeles, California, United States, 90048
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 10381
    Orlando, Florida, United States, 32803
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 17667
    Baton Rouge, Louisiana, United States, 70808
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 14461
    San Antonio, Texas, United States, 78215
    Status
    Not applicable
    Showing {first} - {last} of {total} Results